Introduction {#sec1}
============

Systemic chemotherapy with focal consolidation treatment is the most preferred globe conserving treatment for retinoblastoma (Rb).[@bib1], [@bib2] It has largely replaced external beam radiotherapy (EBRT) as the treatment of choice for conservative management of Rb.[@bib1], [@bib2] Although the success rate of globe salvage techniques is improving, local ocular complications such as retinal detachment (RD) may complicate the Rb management at the time of diagnosis, during and after treatment.[@bib3], [@bib4], [@bib5], [@bib6], [@bib7], [@bib8] Most RD cases in Rb are associated with the use of EBRT combined with other globe-conserving treatments such as systemic chemotherapy or local cryoretinopexy.[@bib3], [@bib4], [@bib5], [@bib6] However, there are only a few reported studies of RD occurring during primary chemoreduction of Rb with no EBRT.[@bib3], [@bib4], [@bib7], [@bib8], [@bib9], [@bib10] Therefore, the aim of our study is to assess the characteristics and outcomes of all our Rb that developed RD after the start of their systemic chemotherapy combined with or without local focal consolidation and without EBRT.

Methods {#sec2}
=======

A retrospective study of all patients treated for Rb between April 2002 and April 2012 at a tertiary hospital center (Birmingham Children's Hospital and Birmingham Midlands Eye Centre, United Kingdom) was performed. The study had approval from the local institutional review board. The study adhered to the tenets of the Declaration of Helsinki, and all patient data extracted were anonymized for analysis. All eyes with no history of exudative or rhegmatogenous RD but developed RD during or after their systemic chemotherapy treatment with or without local focal consolidation treatment were included in the study. The standard treatment in our unit comprised of primary chemoreduction treatment by three to six cycles of "JOE" chemotherapy (Vincristine, Etoposide, and Carboplatin), secondary treatment of local consolidation comprising of trans-scleral cryotherapy with or without laser thermotherapy and salvage treatment for tumor recurrences predominantly by plaque radiotherapy or intra-arterial chemotherapy (IAC) using melphalan. The general demographics and clinical characteristics of the condition were collected which includes age at diagnosis of Rb, gender, laterality of the eye involved, age of the diagnosis of Rb, status of the fellow eye, International Classification of Retinoblastoma (ICRB) on initial examination, and all globe conserving management used. The data collected for the management of the RD includes the type of RD, type of RD intervention, interval between the most recent treatment of Rb and development of RD, age of the development of the RD, time interval to complete resolution of the RD after treatment, follow-up period, postoperative retinal reattachment rate, Rb status, and final VA outcomes. Intra- and postoperative complications were also recorded. Patients with rhegmatogenous RD were treated with scleral buckling surgery, and patients with exudative RD were treated conservatively through observation in the clinic. Cases were presumed exudative if they developed RD with no history of retinal breaks after the completion of the systemic chemotherapy whereas cases were presumed rhegmatogenous if they had developed RD after the completion of their chemotherapy and had previous retinal holes or tears treated with local retinopexy or cryotherapy. The patients with presumed exudative or rhegmatogenous RD features were treated conservatively.

Surgical technique {#sec2.1}
------------------

Informed consent was obtained from all the parents of the patients. The procedure was performed under general anesthesia. A 360-degree conjunctival peritomy was performed followed by the slinging of all four rectus muscles. The location of the breaks was marked and cryotherapy applied. No external drainage was performed. A segmental silicone sponge was placed on the location of the breaks with a 5-0 polyester suture. An anterior chamber paracentesis was performed to ensure the optic nerve head was perfusing. No air or gas tamponade and posturing were required. Postoperative drops include a combination of mydrilate (cyclopentolate 0.5% or 1.0%) twice a day for two weeks and a mixed dexamethasone, neomycin sulphate, and polymyxin B sulphate drops four times a day for one month. Postoperative visits were on the first day, first week, and first month after the surgery. Further follow-up visits were dependable on the appearance of the RD and Rb.

Results {#sec3}
=======

A total of 258 children were treated for Rb over the 10-year period. 160 patients had unilateral Rb while 98 patients had bilateral Rb. Primary enucleation was performed in 139 patients with unilateral disease (86.88%) and one eye in 48 patients with bilateral disease (48.98%). A total of 169 eyes were managed with globe conserving treatment. Ten (5.92%) eyes of 10 patients were complicated with RD during treatment ([Table 1](#tbl1){ref-type="table"}, [Table 2](#tbl2){ref-type="table"}, [Table 3](#tbl3){ref-type="table"}). The mean age of diagnosis of Rb was 6.4 months (range, 3--12 months). The mean age of diagnosis of RD was 12.3 months (range, 4--36 months). The Rb was bilateral in 8 out of 10 patients with RD. The ICRB classification was Group D in half of the patients with RD. In 8 patients, the RD occurred during systemic chemotherapy of which 6 had the RD occurring following the first chemotherapy cycle. The other 2 patients developed RD after their systemic chemotherapy had completed. Five patients were exudative or presumed exudative type of RD while the other 5 patients were rhegmatogenous or presumed rhegmatogenous RD.Table 1Retinal detachment (RD) during retinoblastoma (Rb) management (Clinical characteristics).Table 1Case NoAge at diagnosis of retinoblastoma months/sexRb lateralityICRBSystemic chemotherapyFocal therapyStatus of fellow eye16/FBEDYesYesRegressed Rb24/FBECYesYesEnucleated33/MBECYesYesRegressed Rb47/MRECYesYesNo Rb54/MREDYesNoNo Rb65/FBEDYesYesEnucleated76/MBEBYesYesRegressed Rb812/MBEBYesYesEnucleated99/MBEDYesYesRegressed Rb108/FBEDYesNoUnder treatment[^1]Table 2Retinal detachment (RD) during retinoblastoma (Rb) management (Clinical characteristics).Table 2Case NoAge at development of retinal detachment (Months)RD during chemoreductionCycle of chemoreductionLast local treatment before RDTime interval since last local treatmentRetinal break or thinning18Yes1stNoneN/ANo25Yes1stNoneN/ANo34Yes1stNoneN/ANo45Yes1stNoneN/ANo526NoAfterIAC3 weeksNo610Yes4thCryotherapy + subconjunctival Carboplatin4 weeksYes77Yes1stCryotherapy4 weeksYes813Yes5thLaser6 weeksYes99Yes1stNoneN/AYes1036NoAfterLaser6 weeksNo[^2]Table 3Retinal Detachment (RD) management and outcome.Table 3Case NoRD typeTreatmentTime RD resolvedFinal Rb statusFinal vision1ExudativeObservation20 weeksRecurrenceNo vision as had enucleation2ExudativeObservation10 weeksRegressed0.2 Single Kays (20/32 Snellen)3ExudativeObservation36 weeksRegressed0.86 Crowded Kays (20/145 Snellen)4ExudativeObservation4 weeksUnder treatment0.2 Single Kays (20/32 Snellen)5Presumed\
ExudativeObservationNot resolvedRegressed0.85 Crowded Kays (20/142 Snellen)6RhegmatogenousScleral Buckle6 weeksRegressed0.05 Crowded Kays (20/22 Snellen)7RhegmatogenousScleral buckle8 weeksRegressed0.2 Single Kays (20/32 Snellen)8RhegmatogenousScleral buckle4 weeksRegressed0.98 Crowded Kays (20/191 Snellen)9RhegmatogenousScleral buckleNot completely resolvedRegressed1.84 Crowded Kays (20/1383 Snellen)10Presumed RhegmatogenousObservationNot resolvedRegressedHM[^3]

Exudative retinal detachment {#sec3.1}
----------------------------

Four of the 5 exudative RD eyes occurred after the first cycle of chemotherapy. Four patients did not have focal treatment prior to the development of RD, and RD resolved by conservative observational management. The other remaining RD patient was presumed to be exudative because it developed well over a year after completing systemic chemotherapy and within 3 weeks of IAC treatment with melphalan for multiple recurrences which had not responded to earlier plaque radiotherapy. Although the Rb had regressed with no recurrence, the RD did not resolve and had a complex picture of melphalan-induced chorioretinal atrophy around the RD. Two patients achieved VA of 0.2 Single Kays (20/32 Snellen), and the other two patients achieved 0.85 and 0.86 Crowded Kays (20/142 and 20/145 Snellen), respectively, after the RD had resolved. One patient developed tumor recurrence in their three year follow-up after resolution of RD, and the eye had to be enucleated. The median time for the exudative RD to resolve is 15 weeks (range, 4--36 weeks).

Rhegmatogenous retinal detachment {#sec3.2}
---------------------------------

Four of the 5 rhegmatogenous RD eyes occurred during the course of systemic chemotherapy. The cycle of chemotherapy after which the RD developed varied. The RD developed in the first cycle in 2 cases, and fourth and fifth cycle in the other two patients, respectively ([Table 2](#tbl2){ref-type="table"}). Four patients developed rhegmatogenous RD within four to six weeks of focal therapy (cryotherapy or laser thermotherapy) ([Fig. 1](#fig1){ref-type="fig"}). External approach with scleral buckling procedure and cryotherapy was employed to repair the RD ([Fig. 2](#fig2){ref-type="fig"}). All cases were operated within 2 months of diagnosis of RD. In all operated cases, a retinal break or suspicious area of retinal thinning was identified before or during the operation. In 3 of the 4 operated patients, the median time for the retina to reattach was 6 weeks (range, 4--8 weeks). In the fourth patient, the retina did not reattach. The VA ranged between 0.05 Crowded Kays to 1.84 Crowded Kays (20/22 to 20/1384 Snellen). The fifth patient was presumed to be rhegmatogenous because the RD developed two years after systemic chemotherapy with concurrent multiple cryotherapy and thermotherapy sessions which suggests that there may be retinal thinning or atrophic holes that were not detectable clinically. Therefore, this patient was managed conservatively. The Rb regressed in all the patients. None of the 5 patients with rhegmatogenous RD had to be enucleated for tumor recurrences. There were no intra- and postoperative complications noted.Fig. 1a: Total retinal detachment (RD) within 4 weeks of cryotherapy and subconjunctival carboplatin. b: RD completely settled 6 weeks after scleral buckle surgery.Fig. 1Fig. 2a: Subtotal retinal detachment (RD) within 6 weeks of cryotherapy. b: Completely resolved RD 2 months after scleral buckle surgery.Fig. 2

Discussion {#sec4}
==========

Multi-agent systemic chemotherapy combined with local consolidation therapy is the preferred option in globe conserving treatment of Rb.[@bib1] Complications like RD can occur during these treatments and cause practical difficulties in the management of Rb. Most of the published data about RD complicating Rb management occur following the use of EBRT along with systemic chemotherapy or other local cryoretinopexy or laser photocoagulation treatment.[@bib3], [@bib4], [@bib5], [@bib6] There are a few case series of RD occurring during systemic chemotherapy with no EBRT.[@bib3], [@bib4], [@bib9], [@bib10] We report ten patients (5.91%) which developed RD during primary chemoreduction which is similar to published studies which report a similar rate of around 6%.[@bib4], [@bib5] In our study, 5 patients had features suggestive of exudative RD while the other 5 patients had features suggestive of rhegmatogenous RD.

Exudative RD in Rb tends to present itself as an exophytic tumor when it grows subretinally, and this is associated with significant subretinal seeding of the tumor.[@bib1] With systemic chemotherapy, exudative RD resolves as the Rb shrinks. However, in our case series, four of the 5 exudative RD occurred after the first cycle of systemic chemotherapy without any local focal consolidation treatment. The significance of this finding is not entirely clear, but an excessive initial inflammatory response from chemoreduction or rapid shrinkage of the tumor could be the cause of the exudative RD. Recent treatment of Rb involves the use of IAC which involves the cannulation of the ophthalmic artery to deliver melphalan to the eye.[@bib11] IAC has been shown to resolve 43% of total RD and 100% of partial RD related Rb.[@bib12] However, Shields et al. reports that 6% of rhegmatogenous RD can occur after IAC as well, but this is mostly in advanced eyes with extensive endophytic tumor appearance and atrophic retinal hole after rapid tumor regression.[@bib13] In our case series, we had one similar patient that has developed a presumed exudative RD rather than a rhegmatogenous RD three weeks after the first cycle of IAC with melphalan. The RD did not resolve despite the regression of the Rb and showed a final complex picture of melphalan-induced chorioretinal atrophy combined with retinal pigment epithelial (RPE) changes around the RD. This similar complication was also described by Muen et al. where they had a case of a mixed tractional exudative RD developed after IAC with melphalan.[@bib14]

It has been known that local cryotherapy and photocoagulation causes atrophy of the retina and choroid.[@bib15] This can therefore induce inflammation and increase tractional forces at the vitreoretinal interface leading to the increase risk of developing small retinal holes that causes rhegmatogenous RD. Rhegmatogenous RD associated with Rb is commonly repaired with non-drainage or drainage scleral buckling. The success rate of retinal reattachment following scleral buckling is variable. In a 20-year retrospective study of Rb treated cases by Baumal et al., 5 of the 9 eyes with RD reattached after scleral buckling, but 3 eyes needed enucleation due to the recurrence of the Rb.[@bib3] Other studies using similar techniques had a mixed final retina reattachment rate such as Tawansy et al.[@bib4] (5 out of 14 cases), Bovey,[@bib5] (2 out of 5 cases), Lim et al.[@bib6] (3 out of 5 cases), Saumya et al.[@bib7] (7 out of 7 cases), and Yousef et al.[@bib8] (2 out of 3 cases). Most redetachment cases are due to the recurrence of the Rb which tends to lead to enucleation after the failed RD procedure.[@bib3] Another surgical risk factor influencing the success rate of scleral buckling includes the tractional element of the condition.[@bib8] Four of our 5 rhegmatogenous RD cases developed within four to six weeks after focal therapy of the Rb. These cases were treated with scleral buckling surgery, and 3 cases successfully reattached after 1--2 months. One of our cases was presumed to be rhegmatogenous due to the absence of a retinal break and the long evolution of the RD after systemic chemotherapy, which is not typical of an exudative RD. This is similar to the findings by Bovey et al. and Anagnoste et al.[@bib5], [@bib9] We did not conduct pars plana vitrectomy surgery in any of our patients, but Saumya et al. reported a successful reattachment of two of their cases with vitrectomy combined with tumor recession through retinectomy using melphalan infusion and silicone oil tamponade.[@bib7] Combined vitrectomy with membrane peeling and scleral buckling with gas or silicone oil tamponade has also been reported to be successful in a small case series of three patients with RD with regressed Rb as it helps closed irregular shaped retinal tears at the edge of the tumor scars.[@bib16]

This study has its limitations from the small number of patients and the retrospective nature of study. However, as Rb cases are rare, the findings from this study will help contribute to the pool of knowledge in the management of Rb related RD. In conclusion, exudative RD is a known complication during the systemic chemotherapy for Rb. With long-term conservative management through observation, exudative Rb will tend to resolve by itself. However, supplementary local focal treatment during the systemic treatment of Rb can lead to an increased risk of rhegmatogenous RD. In these situations, most rhegmatogenous RD can be successfully repaired with non-drainage scleral buckling and cryoretinopexy.
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[^1]: Rb: Retinoblastoma; ICRB: International Classification of Retinoblastoma; F: Female; M: Male; BE: Both eyes; RE: Right eye.

[^2]: RD: Retinal detachment; IAC: Intra-arterial chemotherapy with melphalan; N/A: Not applicable.

[^3]: RD: Retinal detachment; Rb: Retinoblastoma; HM: Hand movements.
